The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Open accessAbstract
Cancer-associated IDH mutations are characterized by neomorphic enzyme activity and resultant 2-hydroxyglutarate (2HG) production. Mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specific hypermethylation signature. Furthermore, expression of 2HG-producing IDH alleles in cells induced global DNA hypermethylation. In the AML cohort, IDH1/2 mutations were mutually exclusive with mutations in the α-ketoglutarate-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar epigenetic defects as IDH1/2 mutants. Consistent with these genetic and epigenetic data, expression of IDH mutants impaired TET2 catalytic function in cells. Finally, either expression of mutant IDH1/2 or Tet2 depletion impaired hematopoietic differentiation and increased stem/progenitor cell marker expression, suggesting a shared proleukemogenic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [153]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistently, TET2-mutant immature and myeloid cells present with hypermethylation of active enhancers and perturbed TF activity (28, 32, 53).”
From PU.1-Dependent Enhancer Inhibition Separates Tet2 -Deficient Hematopoiesis from Malignant Transformation (2022) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Figueroa et al., 2010
In the citing paper
“Mutations in isocitrate dehydrogenase isoform-1 (IDH1) and IDH2 generate the oncometabolite D-2-hydroxyglutarate (D-2HG), which inhibits epigenetic enzymes including histone demethylases and the Ten-eleven translocation (TET) family of 5-methylcytosine hydroxylases.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“These effects contribute to tumor initiation in acute myelogenous leukemia (AML) by resulting in persistent histone and DNA methylation and impaired cellular differentiation (25).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [117]
In the citing paper
“In addition, TET2 inactivation is sufficient to promote hematopoietic stem cell self-renewal and to block differentiation (Figueroa et al., 2010; Li et al., 2011; Moran-Crusio et al., 2011; Noushmehr et al., 2010; Turcan et al., 2012; Losman et al., 2013).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“In this regard, TET2 and IDH mutations are both found in acute myelogenous leukemia and are mutually exclusive, consistent with the idea that R-2HG produced by mutant IDH provides an alterative means of inactivating TET2 (Figueroa et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“R-2HG, succinate, and fumarate are all capable of inhibiting multiple 2-oxoglutarate-dependent dioxygenases, including the JmjC histone demethylases and TET proteins, when present at sufficiently high concentrations (Figure 6B) (Cervera et al., 2009; Chowdhury et al., 2011; Figueroa et al., 2010; Koivunen et al., 2012; Lu et al., 2012; Smith et al., 2007; Turcan et al., 2012; Xiao et al., 2012; Xu”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“More recently, we have also learnt how the catalytic activity of EZH2 can be compromised by so called 'oncohistones' 100 (Figure 3).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“Around 30% of all paediatric glioblastomas contain mutations in histone genes resulting in H3K27M, H3K27I and H3G34V/R substitutions (reviewed in REF. 100 ).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“in a large acute myelogenous leukaemia (AML) cohort, TET2 was found to be mutually exclusive with gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 (REF.65).”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [65]
In the citing paper
“Heterozygous, inactivating ten-eleven translocation 2 (TET2) mutations and neomorphic isocitrate dehydrogenase (IDH) mutations are recurrent and mutually exclusive in acute myeloid leukaemia genomes.”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [5]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [172]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“IDH mutations in AML are mutually exclusive with inactivating mutations in TET2 methylcytosine hydroxylases, further implicating mutant IDH as a bona fide driver of epigenetic remodeling (Figueroa et al., 2010).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“Mutant IDH2 [Arg140→Gln140 (R140Q)], which promotes α-KG depletion/2-HG production, promotes DNA hypermethylation in hematopoietic cells and can inhibit myeloid differentiation when overexpressed in bone marrow stem cells (79).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“multiple groups have found that IDH mutant expression and 2HG elevation can inhibit the TET family of enzymes that hydroxylate 5’-methylcytosine (Figueroa et al., 2010; Turcan et al., 2012; Xu et al., 2011)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“TET2 mutant AML samples displayed an overlapping DNA hypermethylation signature with samples having IDH1 or IDH2 mutations”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“neomorphic mutations of IDH1 or IDH2 and TET2 loss-of-function mutations were found to be mutually exclusive in a large AML cohort”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“In both cell types, the overexpression of IDH mutants blocked acquisition of mature myeloid markers while increasing the expression of stem cell markers (Figueroa et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“shRNA knockdown of TET2 recapitulated the effect of IDH mutant overexpression on blocking hematopoietic cell differentiation (Figueroa et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“mutations in IDH1/2 and in the 5-methylcytosine hydroxylase TET2 occur frequently in acute myelogenous leukemia”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“primary IDH1- or IDH2-mutant tumors showed evidence of extensively altered histone and DNA methylation in vivo”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“the mutations were found to be mutually exclusive”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“high concentrations of 2-HG inhibited the function of α-ketoglutarate-dependent histone demethylases and 5-methylcytosine hydroxylases in vitro”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“metabolomic profiling of mIDH1/2 gliomas revealed significant alterations in cellular metabolism, an effect recapitulated with the exogenous addition of D-2-HG134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
In the citing paper
“This metabolic rewiring resulted in a decrease in a common dipeptide found in the brain N-acetyl-aspartyl-glutamate (NAAG), and NAAG levels were found to be significantly lower in IDH-mutant human glioma tissue134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationIto, S., D’Alessio, A. C., Taranova, O., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,628
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Histone demethylation by a family of JmjC domain-containing proteins
Tsukada, Y.-I., Fang, J., Erdjument‐Bromage, H., Warren, M., Borchers, C. H., Tempst, P., & Zhang, Y. (2005) · Nature · doi:10.1038/nature04433 · Cited by 2,244
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citation
Flagged first, then by citations
1 of the 35 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 1,005
Aucagne, R., Droin, N., Paggetti, J., Lagrange, B., Largeot, A., Hammann, A., Bataille, A., Martin, L., Yan, K.-P., Fenaux, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45213 · Cited by 117
Ho, P. A., Kutny, M. A., Alonzo, T. A., Gerbing, R. B., Joaquin, J., Raimondi, S. C., Gamis, A. S., & Meshinchi, S. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23179 · Cited by 123
The molecular pathogenesis of the myelodysplastic syndromes
Pellagatti, A., & Boultwood, J. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12515 · Cited by 120
Playing TETris with DNA modifications
Delatte, B., Deplus, R., & Fuks, F. (2014) · The EMBO Journal · doi:10.15252/embj.201488290 · Cited by 118
Müller, T., Gessi, M., Waha, A., Isselstein, L., Luxen, D., Freihoff, D., Freihoff, J., Becker, A. J., Simon, M., Hammes, J., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.017 · Cited by 116
Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma
Jo, V. Y., Chau, N. G., Hornick, J. L., Krane, J. F., & Sholl, L. M. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.239 · Cited by 116
Genetic alterations in Krebs cycle and its impact on cancer pathogenesis
Sajnani, K., Islam, F., Smith, R. A., Gopalan, V., & Lam, A. K.-Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.02.008 · Cited by 121
Modrek, A. S., Golub, D., Khan, T. A., Bready, D., Prado, J., Bowman, C., Deng, J., Zhang, G., Rocha, P. P., Raviram, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.009 · Cited by 118
Molecular Subtypes of Prostate Cancer
Arora, K., & Barbieri, C. E. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0707-9 · Cited by 119
Huang, K., Han, Y., Chen, Y., Shen, H., Zeng, S., & Cai, C. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02205-6 · Cited by 121
The role of 5-hydroxymethylcytosine in human cancer
Pfeifer, G. P., Xiong, W., Hahn, M. A., & Jin, S. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1896-7 · Cited by 118
Ohka, F., Natsume, A., Motomura, K., Kishida, Y., Kondo, Y., Abé, T., Nakasu, Y., Namba, H., Wakai, K., Fukui, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023332 · Cited by 116
Mutant IDH is sufficient to initiate enchondromatosis in mice
Hirata, M., Sasaki, M., Cairns, R. A., Inoue, S., Puviindran, V., Li, W. Y., Snow, B. E., Jones, L. D., Wei, Q., Sato, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424400112 · Cited by 115
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Popovic, R., & Licht, J. D. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0076 · Cited by 119
Self-citationFrequent IDH2 R172 mutations in undifferentiated and poorly‐differentiated sinonasal carcinomas
Doğan, S., Chute, D. J., Xu, B., Ptashkin, R. N., Chandramohan, R., Casanova, J., Nafa, K., Bishop, J. A., Chiosea, S. I., Stelow, E. B., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4915 · Cited by 115
Norsworthy, K. J., Mulkey, F. A., Scott, E., Ward, A. F., Przepiorka, D., Charlab, R., Dorff, S. E., Deisseroth, A., Kazandjian, D. G., Sridhara, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0834 · Cited by 115
Traina, F., Visconte, V., Jankowska, A. M., Makishima, H., O’Keefe, C. L., Elson, P. J., Han, Y., Hsieh, F. H., Sekeres, M. A., Mali, R. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043090 · Cited by 122
Serine Metabolism: Some Tumors Take the Road Less Traveled
DeBerardinis, R. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.004 · Cited by 121
Chotirat, S., Thongnoppakhun, W., Promsuwicha, O., Boonthimat, C., & Auewarakul, C. U. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-5 · Cited by 116
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
Vasanthakumar, A., & Godley, L. A. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.02.009 · Cited by 116
Self-citationGenetic and epigenetic determinants of AML pathogenesis
Cai, S. F., & Levine, R. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.08.001 · Cited by 117
Self-citationInterplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer
Huo, M., Zhang, J., Huang, W., & Wang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.793428 · Cited by 117
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia
Rampal, R. K., & Figueroa, M. E. (2016) · Haematologica · doi:10.3324/haematol.2015.141796 · Cited by 114
Self-citationPRMT4 Blocks Myeloid Differentiation by Assembling a Methyl-RUNX1-Dependent Repressor Complex
Vu, L., Perna, F., Wang, L., Voza, F. A., Figueroa, M. E., Tempst, P., Erdjument‐Bromage, H., Gao, R., Chen, S., Paietta, E. M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.025 · Cited by 113
Self-citationLópez-Bertoni, H., Johnson, A., Rui, Y., Lal, B., Sall, S., Malloy, M., Coulter, J. B., Lugo-Fagundo, M. F., Shudir, S., Khela, H. S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00857-0 · Cited by 113
Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives
Ibrahim, J., Peeters, M., Camp, G. V., & de Beeck, K. O. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.10.015 · Cited by 116
Desideri, E., Vegliante, R., & Ciriolo, M. R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.023 · Cited by 116
Jin, G., Reitman, Z. J., Spasojevic, I., Batinic-Haberle, I., Yang, J., Schmidt-Kittler, O., Bigner, D. D., & Yan, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016812 · Cited by 112
Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells
Shenoy, N., Bhagat, T., Nieves, E., Stenson, M., Lawson, J., Choudhary, G. S., Habermann, T., Nowakowski, G., Singh, R., Wu, X., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.65 · Cited by 111
Advances in DNA methylation: 5-hydroxymethylcytosine revisited
Dahl, C., Grønbæk, K., & Guldberg, P. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.02.013 · Cited by 117
Profiling metabolic networks to study cancer metabolism
Hiller, K., & Metallo, C. M. (2012) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2012.11.001 · Cited by 113
Oxidative stress and hypoxia in normal and leukemic stem cells
Testa, U., Labbaye, C., Castelli, G., & Pelosi, E. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.04.012 · Cited by 118
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
Fenouille, N., Bassil, C. F., Ben‐Sahra, I., Benajiba, L., Alexe, G., Ramos, A., Pikman, Y., Conway, A. S., Burgess, M. R., Li, Q., et al. (2017) · Nature Medicine · doi:10.1038/nm.4283 · Cited by 112
TET2 as an epigenetic master regulator for normal and malignant hematopoiesis
Nakajima, H., & Kunimoto, H. (2014) · Cancer Science · doi:10.1111/cas.12484 · Cited by 117
A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG
Pietrak, B., Zhao, H., Qi, H., Quinn, C. J., Gao, E. N., Boyer, J. G., Concha, N. O., Brown, K., Duraiswami, C., Wooster, R. F., et al. (2011) · Biochemistry · doi:10.1021/bi200499m · Cited by 112
Shih, A. H., Meydan, C., SHANK, K. R., Garrett-Bakelman, F. E., Ward, P. S., Intlekofer, A. M., Nazir, A., Stein, E. M., Knapp, K. M., Glass, J. L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1049 · Cited by 113
Self-citationIsocitrate dehydrogenase inhibitors in acute myeloid leukemia
Liu, X., & Gong, Y. (2019) · Biomarker Research · doi:10.1186/s40364-019-0173-z · Cited by 111
Stein, E. M., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Roboz, G. J., Collins, R. H., Sekeres, M. A., Stone, R. M., Attar, E. C., Frattini, M. G., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30284-4 · Cited by 109
Self-citationWang, Y., Wild, A. T., Turcan, Ş., Wu, W., Sigel, C., Klimstra, D. S., Ma, X., Gong, Y., Holland, E. C., Huse, J. T., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz3221 · Cited by 109
Saqcena, M., Leandro-Garcia, L. J., Mååg, J. L. V., Tchekmedyian, V., Krishnamoorthy, G. P., Tamarapu, P. P., Tiedje, V., Reuter, V. P., Knauf, J. A., de Stanchina, E., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0735 · Cited by 109
Tothill, R. W., Li, J., Mileshkin, L., Doig, K., Siganakis, T., Cowin, P. A., FELLOWES, A. P., Semple, T. J., Fox, S. B., Byron, K. A., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4251 · Cited by 108
The Epigenetic Landscape of Acute Myeloid Leukemia
O’Brien, E. C., Prideaux, S. M., & Chevassut, T. J. T. (2014) · Advances in Hematology · doi:10.1155/2014/103175 · Cited by 115
van den Bent, M. J., Gravendeel, L. A. M., Gorlia, T., Kros, J. M., Lapre, L., Wesseling, P., Teepen, J. L. J. M., Idbaïh, A., Sanson, M., Smitt, P. A. E. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1274 · Cited by 108
Colvin, H. S., Nishida, N., Konno, M., Haraguchi, N., Takahashi, H., Nishimura, J., Hata, T., Kawamoto, K., Asai, A., Tsunekuni, K., et al. (2016) · Scientific Reports · doi:10.1038/srep36289 · Cited by 111
Epigenomic Reprogramming as a Driver of Malignant Glioma
Phillips, R. E., Soshnev, A. A., & Allis, C. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.008 · Cited by 111
ALDH1A3 Coordinates Metabolism With Gene Regulation in Pulmonary Arterial Hypertension
Li, D., Shao, N., Moonen, J.-R. A. J., Zhao, Z., Shi, M., Otsuki, S., Wang, L., Nguyen, T., Yan, E., Marciano, D. P., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.048845 · Cited by 108
CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors
Reed, S. C., Croessmann, S., & Park, B. H. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2598 · Cited by 112
Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program
Park, S.-M., Gönen, M., Vu, L., Minuesa, G., Tivnan, P., Barlowe, T. S., Taggart, J., Lu, Y., Deering, R. P., Hacohen, N., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78440 · Cited by 110
Self-citationPutiri, E. L., Tiedemann, R. L., Thompson, J. J., Liu, C., Ho, T. H., Choi, J.-H., & Robertson, K. D. (2014) · Genome biology · doi:10.1186/gb-2014-15-6-r81 · Cited by 111
Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies
Masui, K., Cloughesy, T. F., & Mischel, P. S. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01238.x · Cited by 113
Chambwe, N., Kormáksson, M., Geng, H., De, S., Michor, F., Johnson, N. A., Morin, R. D., Scott, D. W., Godley, L. A., Gascoyne, R. D., et al. (2014) · Blood · doi:10.1182/blood-2013-07-509885 · Cited by 109
Self-citationLi, L., Paz, A. C., Wilky, B. A., Johnson, B. A., Galoian, K. A., Rosenberg, A. E., Hu, G., Tinoco, G., Bodamer, O. A., & Trent, J. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133813 · Cited by 107
Xu, Q., Li, Y., Lv, N., Jing, Y., Xu, Y., Li, Y., Li, W., Yao, Z., Chen, X., Huang, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2628 · Cited by 111
Self-citationEpigenetic Priming in Cancer Initiation
Vicente‐Dueñas, C., Hauer, J., Cobaleda, C., Borkhardt, A., & Sánchez-Garcı́a, I. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.04.007 · Cited by 107
Clinical advances in targeting epigenetics for cancer therapy
Feng, S., & Carvalho, D. D. D. (2021) · FEBS Journal · doi:10.1111/febs.15750 · Cited by 109
Targeting glucose metabolism in patients with cancer
Elf, S., & Chen, J. (2013) · Cancer · doi:10.1002/cncr.28501 · Cited by 108
Myelodysplastic syndromes: moving towards personalized management
Hellström‐Lindberg, E., Tobiasson, M., & Greenberg, P. L. (2020) · Haematologica · doi:10.3324/haematol.2020.248955 · Cited by 109
Heuck, C. J., Mehta, J., Bhagat, T. D., Gundabolu, K., Yu, Y., Khan, S. N., Chrysofakis, G., Schinke, C., Tariman, J. D., Vickrey, E., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202493 · Cited by 111
Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations
Kerr, D. A., Lopez, H. U., Deshpande, V., Hornicek, F. J., Duan, Z., Zhang, Y., Rosenberg, A. E., Borger, D. R., & Nielsen, G. P. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827ab703 · Cited by 105
Epigenomics of leukemia: from mechanisms to therapeutic applications
Florean, C., Schnekenburger, M., Grandjenette, C., Dicato, M. A., & Diederich, M. F. (2011) · Epigenomics · doi:10.2217/epi.11.73 · Cited by 107
Mutations of myelodysplastic syndromes (MDS): An update
Ganguly, B. B., & Kadam, N. N. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.04.009 · Cited by 108
Hasselbalch, H. C., & Holmström, M. O. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0700-2 · Cited by 106
TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition
Morin, A., Goncalves, J., Moog, S., Castro‐Vega, L. J., Job, S., Buffet, A., Fontenille, M., Woszczyk, J., Gimenez‐Roqueplo, A., Letouzé, É., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.022 · Cited by 110
The Metabolic Alterations of Cancer Cells
Sciacovelli, M., Gaude, E., Hilvo, M., & Frezza, C. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416618-9.00001-7 · Cited by 108
TET family dioxygenases and the TET activator vitamin C in immune responses and cancer
Yue, X., & Rao, A. (2020) · Blood · doi:10.1182/blood.2019004158 · Cited by 106
Epigenetic Regulation of Genomic Stability by Vitamin C
Brabson, J. P., Leesang, T. E., Mohammad, S., & Cimmino, L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.675780 · Cited by 111
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
Johannessen, T.-C. A., Mukherjee, J., Viswanath, P., Ohba, S., Ronen, S. M., Bjerkvig, R., & Pieper, R. O. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0141 · Cited by 105
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
Dimitrov, L., Hong, C. S., Yang, C., Zhuang, Z., & Heiss, J. D. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11047 · Cited by 108
IDH inhibition in gliomas: from preclinical models to clinical trials
Rudà, R., Horbinski, C., van den Bent, M. J., Preusser, M., & Soffietti, R. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00967-7 · Cited by 105
Chatterjee, R., & Vinson, C. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.02.014 · Cited by 109
Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets
Lawlor, E. R., & Thiele, C. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1921 · Cited by 104
How metabolites modulate metabolic flux
Wegner, A., Meiser, J., Weindl, D., & Hiller, K. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.11.008 · Cited by 108
Stefano, B. D., Collombet, S., Jakobsen, J. S., Wierer, M., Sardina, J. L., Lackner, A., Stadhouders, R., Segura-Morales, C., Francesconi, M., Limone, F., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3326 · Cited by 106
Non‐canonical Bases in the Genome: The Regulatory Information Layer in DNA
Carell, T., Kurz, M. Q., Müller, M., Rossa, M., & Spada, F. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201708228 · Cited by 104
Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications
Yang, X., Wong, M. P. M., & Ng, R. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184576 · Cited by 105
Grafodatskaya, D., Chung, B. H., Butcher, D. T., Turinsky, A. L., Goodman, S. J., Choufani, S., Chen, Y. A., Lou, Y., Zhao, C., Rajendram, R., et al. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-1 · Cited by 103
Gentile, T. L., Lü, C., Lodato, P. M., Tse, S., Olejniczak, S. H., Witze, E. S., Thompson, C. B., & Wellen, K. E. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01495-12 · Cited by 102
Self-citationMolecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms
Grinfeld, J., Nangalia, J., & Green, A. R. (2016) · Haematologica · doi:10.3324/haematol.2014.113845 · Cited by 108
Role of Methylation in Pro- and Anti-Cancer Immunity
Mehdi, A., & Rabbani, S. A. (2021) · Cancers · doi:10.3390/cancers13030545 · Cited by 102
Mutational landscape of AML with normal cytogenetics: Biological and clinical implications
Martelli, M. P., Sportoletti, P., Tiacci, E., Martelli, M. F., & Falini, B. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.11.001 · Cited by 104
Thomas, G. E., Egan, G., García‐Prat, L., Botham, A. D., Voisin, V., Patel, P. S., Hoff, F. W., Chin, J., Nachmias, B., Kaufmann, K. B., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00925-9 · Cited by 102
Epigenetic regulators in cancer therapy and progression
Marei, H. E. S. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01003-7 · Cited by 116
Cancer cell metabolism and the modulating effects of nitric oxide
Chang, C.-F., Diers, A. R., & Hogg, N. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.012 · Cited by 103
Vitamin C – A new player in regulation of the cancer epigenome
Gillberg, L., Ørskov, A. D., Liu, M., Harsløf, L. B. S., Jones, P. A., & Grønbæk, K. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.001 · Cited by 100
Chuang, K., Whitney‐Miller, C. L., Chu, C., Zhou, Z., Dokus, M. K., Schmit, S., & Barry, C. T. (2015) · Hepatology · doi:10.1002/hep.27816 · Cited by 100
Geng, H., Brennan, S. K., Milne, T. A., Chen, W., Li, Y., Hurtz, C., Kweon, S.-M., Zickl, L., Shojaee, S., Neuberg, D. S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0208 · Cited by 103
Self-citationMeyer, S. E., Qin, T., Muench, D. E., Masuda, K., Venkatasubramanian, M., Orr, E., Suarez, L., Gore, S. D., Delwel, R., Paietta, E. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0008 · Cited by 101
Self-citationThe myelodysplastic syndrome as a prototypical epigenetic disease
Issa, J. J. (2013) · Blood · doi:10.1182/blood-2013-02-451757 · Cited by 103
Yan, F., Shen, N., Pang, J. X., Zhang, Y. W., Rao, E., Bode, A. M., Al‐Kali, A., Zhang, D., Litzow, M. R., Li, B., et al. (2016) · Leukemia · doi:10.1038/leu.2016.349 · Cited by 100
Lin, J., Yao, D., Qian, J., Chen, Q., Qian, W., Li, Y., Yang, J. C., Wang, C., Chai, H., Qian, Z. Y., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1352-7 · Cited by 99
Self-citationMitochondrial DNA mutations in ageing and cancer
Smith, A. L. M., Whitehall, J. C., & Greaves, L. C. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13291 · Cited by 105
Debarri, H., Lebon, D., Roumier, C., Cheok, M. H.-C., Marceau‐Renaut, A., Nibourel, O., Geffroy, S., Hélevaut, N., Rousselot, P. H., Gruson, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5645 · Cited by 108
The mitochondrial side of epigenetics
Castegna, A., Iacobazzi, V., & Infantino, V. (2015) · Physiological Genomics · doi:10.1152/physiolgenomics.00096.2014 · Cited by 100
Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice
Muto, H., Sakata‐Yanagimoto, M., Nagae, G., Shiozawa, Y., Miyake, Y., Yoshida, K., Enami, T., Kamada, Y., Kato, T., Uchida, K., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.83 · Cited by 101
IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors
Mellai, M., Piazzi, A., Caldera, V., Monzeglio, O., Cassoni, P., Valente, G., & Schiffer, D. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0596-3 · Cited by 97
Characterization of acute myeloid leukemia based on levels of global hydroxymethylation
Kroeze, L. I., Aslanyan, M. G., van Rooij, A., Koorenhof‐Scheele, T. N., Massop, M., Carell, T., Boezeman, J. B. M., Marie, J., Halkes, C. J. M., de Witte, T., et al. (2014) · Blood · doi:10.1182/blood-2013-08-518514 · Cited by 99
The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?
Abla, H., Sollazzo, M., Gasparre, G., Iommarini, L., & Porcelli, A. M. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.031 · Cited by 99
Venugopal, S., Takahashi, K., Daver, N. G., Maiti, A., Borthakur, G. M., Loghavi, S., Short, N. J., Ohanian, M. N., Masárová, L., Issa, G. C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-021-00604-2 · Cited by 96
Molenaar, R. J., Thota, S., Nagata, Y., Patel, B. J., Clemente, M. J., Przychodzen, B. P., Hirsch, C. M., Viny, A. D., Hosano, N., Bleeker, F. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.91 · Cited by 101
The role of 5-hydroxymethylcytosine in development, aging and age-related diseases
López, V., Fernández, A. F., & Fraga, M. F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.05.002 · Cited by 101
Metadata
- Authors
- Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., Tallman, M. S., Sun, Z., Wolniak, K., Peeters, J. K., Liu, W., Choe, S. E., Fantin, V. R., Paietta, E., Löwenberg, B., Licht, J. D., Godley, L. A., Delwel, R., Valk, P. J. M., Thompson, C. B., Levine, R. L., & Melnick, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Abramson Cancer Center (US)
- Weill Cornell Medicine (US)
- University of Chicago (US)
- Moffitt Cancer Center (US)
- Harvard University (US)
- Northwestern University (US)
- Erasmus MC (NL)
- Agios Pharmaceuticals (United States) (US)
- Montefiore Medical Center (US)
- Corresponding author
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- ORCID
- Abdel-Wahab, Omar
- Ward, Patrick S.
- Patel, Jay
- Shih, Alan
- Li, Yushan
- Bhagwat, Neha
- Vasanthakumar, Aparna
- Fernandez, Hugo F.
- Tallman, Martin S.
- Sun, Zhuoxin
- Wolniak, Kristy
- Liu, Wei
- Choe, Sung E.
- Fantin, Valeria R.
- Paietta, Elisabeth
- Löwenberg, Bob
- Licht, Jonathan D.
- Godley, Lucy A.
- Delwel, Ruud
- Valk, Peter J.M.
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 18
- Issue
- 6
- Pages
- 553-567
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4105845
- OpenAlex
- W2078972833
- Cited by
- 2,766
- References
- 35
- Citations by year
- 2026: 92 · 2025: 114 · 2024: 156 · 2023: 158 · 2022: 155 · 2021: 213 · 2020: 183 · 2019: 165 · 2018: 178 · 2017: 196 · 2016: 186 · 2015: 193 · 2014: 217 · 2013: 214 · 2012: 191
- FWCI
- 111.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- Agios Pharmaceuticals
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL082950)
- National Cancer Institute (CA114737, R01CA105463, U54CA143798, U24CA114737, R01CA173636, U10CA021115, CA 21115)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, IDH2 mutation, acute myeloid leukemia, DNA hypermethylation, 2-hydroxyglutarate, TET2, hematopoietic differentiation, epigenetic dysregulation, stem/progenitor cells
- MeSH terms
- MDS1 and EVI1 Complex Locus Protein, Cell Differentiation, DNA-Binding Proteins, Humans, Hydroxylation, Isocitrate Dehydrogenase, Mutation, Phenotype, Proto-Oncogene Proteins, Proto-Oncogenes, Transcription Factors, Leukemia, Myeloid, Acute, DNA Methylation, Myeloid Cells, 5-Methylcytosine, Dioxygenases, GATA1 Transcription Factor, Gene Regulatory Networks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
